2023
Effect of inferior vena cava filter placement position on device complications
Grubman S, Kostiuk V, Brahmandam A, Tonnessen B, Mojibian H, Schneider E, Guzman R, Chaar C. Effect of inferior vena cava filter placement position on device complications. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2023, 11: 1165-1174.e2. PMID: 37356713, DOI: 10.1016/j.jvsv.2023.05.020.Peer-Reviewed Original ResearchDevice-related mortalityDeep vein thrombosisIVC thrombosisIVC filtersRenal veinDevice complicationsCause mortalityPulmonary embolismVein thrombosisGroup CInferior vena cava filterAccess site hematomaPrimary end pointBaseline patient characteristicsSingle tertiary centerLong-term complicationsLong-term outcomesMultivariate logistic regressionRisk of thrombosisVena cava filtersLong-term thrombosisDistribution of sexEligible patientsSite hematomaPatient characteristics
2022
Placement and retrieval of bilateral iliac vein filters in patients with mega cava
Brahmandam A, Grubman S, Salem R, Davis KA, Tonnessen BH, Guzman RJ, Chaar C. Placement and retrieval of bilateral iliac vein filters in patients with mega cava. Journal Of Vascular Surgery Cases And Innovative Techniques 2022, 8: 610-615. PMID: 36248380, PMCID: PMC9556588, DOI: 10.1016/j.jvscit.2022.08.002.Peer-Reviewed Original ResearchVenous thromboembolismTherapeutic anticoagulationTemporary inferior vena cava filterInferior vena cava filterRecurrent venous thromboembolismBilateral iliac veinsInferior vena cavaVena cava filtersPulmonary embolismIliac veinVena cavaCava filtersPatientsSuccessful placementTemporary interruptionAnticoagulationContraindicationsCavaPresent reportThromboembolismEmbolismComplicationsPlacement
2004
Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer
Tonnessen B, Money S. Low-Molecular-Weight Heparin Versus Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients With Cancer. Perspectives In Vascular Surgery And Endovascular Therapy 2004, 16: 144-146. DOI: 10.1177/153100350401600217.Peer-Reviewed Original ResearchWeight heparin groupRecurrent venous thromboembolismRecurrent thromboembolismVenous thromboembolismWeight heparinAnticoagulation groupHeparin groupOpen-label clinical trialLowmolecular-weight heparinAcute venous thromboembolismOral anticoagulant therapyDeep vein thrombosisGroup of patientsMolecular weight heparinLower mortality rateOral anticoagulantsAnticoagulant therapyPulmonary embolismVein thrombosisCancer patientsClinical trialsEffective therapyThromboembolismMortality ratePatients